Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153772 · ClinicalTrials.gov registry record · Phase 2
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
A Phase 2 study of Neuroendocrine Tumors, sponsored by Orano Med.
- Active
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 4
- Study locations
NCT05153772 is a Phase 2 study of Neuroendocrine Tumors that is active but no longer recruiting, run by Orano Med. The registered enrollment target is 69 participants, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (61% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05153772, a Phase 2 study of Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Orano Med.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 4
- Study locations
Study Summary
Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)
Conditions Studied
Interventions
- DRUG AlphaMedix
Study Locations (4)
Colorado
- Rocky Mountain Cancer Center - Denver
Florida
- Moffitt Cancer Center - Tampa
Louisiana
- Louisiana State University (LSU) Health Sciences Center - New Orleans - Metairie
Texas
- Excel Diagnostics and Nuclear Oncology Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05153772
The ClinicalTrials.gov registry entry for NCT05153772 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (61% lower). The listed sponsor is Orano Med, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which AlphaMedix is the first listed.
NCT05153772 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05153772 about?
NCT05153772 is a clinical study titled "Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients". Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)
What is the current status of trial NCT05153772?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2021-12-21. Estimated completion is 2028-10.
What conditions does trial NCT05153772 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT05153772?
The interventions under investigation include: AlphaMedix (DRUG).
Who is sponsoring clinical trial NCT05153772?
This trial is sponsored by Orano Med, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05153772 being conducted?
This trial has 4 study locations across Colorado, Florida, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.